H.C. Wainwright analyst Raghuram Selvaraju upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a $30 price target The stock’s current valuation is not appropriate given the potential of sonelokimab, the analyst tells investors in a research note. The firm says that while the regulatory pathway is yet to be determined, existing precedent “seems encouraging.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi
- Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study
- MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents
- Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study